Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings

NCT00830570 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this quasi-experiment study, which could also be classified as a prospective observational intervention study, is to assess the impact of cytochrome P450 2C9 (CYP 2C9) and vitamin K epoxide reductase complex, subunit 1 (VKORC1) testing within a primary patient care setting.

Interventions

  • OTHER CYP 2C9 and VKORC1 Testing for Warfarin

Study Locations (1)

New Jersey

  • Medco Health Solutions, Inc. — Franklin Lakes

Trial Details

FieldValue
Enrollment Target 1,635 participants
Start Date 2007-07
Est. Completion 2010-01

Sponsor

Medco Health Solutions

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00830570

The ClinicalTrials.gov registry entry for NCT00830570 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,635 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medco Health Solutions, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 7 conditions, with Venous Thromboembolism appearing as the primary indexed condition, and to 1 intervention — of which CYP 2C9 and VKORC1 Testing for Warfarin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00830570 reports 1 study location spanning 1 distinct geographic area — top geographies include New Jersey. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00830570 about?

NCT00830570 is a clinical study titled "The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings". The purpose of this quasi-experiment study, which could also be classified as a prospective observational intervention study, is to assess the impact of cytochrome P450 2C9 (CYP 2C9) and vitamin K epoxide reductase complex, subunit 1 (VKORC1) testing within a primary patient care setting.

What is the current status of trial NCT00830570?

This trial is currently completed. The enrollment target is 1,635 participants. The study started on 2007-07. Estimated completion is 2010-01.

What conditions does trial NCT00830570 study?

This clinical trial studies the following conditions: Venous Thromboembolism, Vascular Diseases, Thrombosis, Thromboembolism, Embolism and Thrombosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00830570?

The interventions under investigation include: CYP 2C9 and VKORC1 Testing for Warfarin (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00830570?

This trial is sponsored by Medco Health Solutions, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00830570 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial